Ahmed Abdelrahman Abdelgalil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmed Abdelrahman Abdelgalil has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Hassan Bakheit
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
3 shared publications Badraddin M H Al-Hadiya
Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, TAIF, KSU
2 shared publicationsA.M. Haseeb
1 shared publicationAbd-Elwahab Hassan Mohammed
Department of Pharmacology, College of Pharmacy, University of Gezira, Sudan
1 shared publicationAbdullah M. Al-Mohizea
1 shared publicationAbdullah Mohammed Al-Mohizea
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
1 shared publication
Latest Publications
- 1 September 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 882, 173229
The protective effect of losartan against sorafenib induced cardiotoxicity: Ex-vivo isolated heart and metabolites profiling studies in rat
- 1 September 2020
- Published by Elsevier in European Journal of Pharmacology
- Vol. 882, 173229
The protective effect of losartan against sorafenib induced cardiotoxicity: Ex-vivo isolated heart and metabolites profiling studies in rat
- Open Access
- 1 May 2020
- Published by Elsevier in Saudi Journal of Biological Sciences
- Vol. 27 (5) , 1380-1383
Cigarette waste: Assessment of hazard to the environment and health in Riyadh city
- 1 May 2020
- Published by Elsevier in Saudi Journal of Biological Sciences
- Vol. 27 (5) , 1380-1383
Open AccessCigarette waste: Assessment of hazard to the environment and health in Riyadh city
- 5 November 2018
- Published by Bentham Science Publishers Ltd. in Current Analytical Chemistry
- Vol. 14 (6) , 634-640
Rapid UPLC Tandem Triple Quadrupole Mass Spectrometry Method for Determination of Regorafenib in Plasma
Background: Regorafenib is a multikinase inhibitor, indicated for the treatment of metastatic colorectal cancer and locally advanced, unresectable or metastatic gastrointestinal stromal tumor. Objective: A simple and fast, validated bioanalytical method is required for pre-clinical or clinical safety and efficacy investigations and possible pharmacokinetic interaction of regorafenib. Method: Regorafenib and sorafenib were eluted on Acquity UPLC®BEH C18 column. Elution was carried out by pumping mobile phase [methanol (0.1% formic acid): water (85:15%)] at 200µl/min flow rate. Mass detector was operated in multiple-reaction monitoring mode. Deprotonated ions [M-H]¯ of regorafenib and sorafenib were fragmented and monitored. Results: Daughter fragments of regorafenib (m/z 481.1 > 194, m/z 481.1 > 260) and sorafenib (m/z 463 > 193.99, m/z 463 > 268.1) were determined in negative electrospray ionization mode. Linear calibration curve of range 50-2500 ng/ml was prepared in plasma. Method was selective, since there was no interfering peak at regorafenib retention time. Coefficient of variation for inter-day precision at three quality control concentrations were 17.6% at lower limit of quantitation, 6.3% at middle limit, and 2.9% at highest limit of quantitation. Accuracy of the method ranges between 96% to 105.3%. Recovery of drug from blank plasma at quality control concentrations varies between 82.53 to 105.66%. Conclusion: The developed method was successfully validated by adopting US FDA guidance for bioanalytical methods. The method is simple, quick and can be adopted for regorafenib estimation in other biological fluids with necessary modifications.
- 5 November 2018
- Published by Bentham Science Publishers Ltd. in Current Analytical Chemistry
- Vol. 14 (6) , 634-640
Rapid UPLC Tandem Triple Quadrupole Mass Spectrometry Method for Determination of Regorafenib in Plasma
Background: Regorafenib is a multikinase inhibitor, indicated for the treatment of metastatic colorectal cancer and locally advanced, unresectable or metastatic gastrointestinal stromal tumor. Objective: A simple and fast, validated bioanalytical method is required for pre-clinical or clinical safety and efficacy investigations and possible pharmacokinetic interaction of regorafenib. Method: Regorafenib and sorafenib were eluted on Acquity UPLC®BEH C18 column. Elution was carried out by pumping mobile phase [methanol (0.1% formic acid): water (85:15%)] at 200µl/min flow rate. Mass detector was operated in multiple-reaction monitoring mode. Deprotonated ions [M-H]¯ of regorafenib and sorafenib were fragmented and monitored. Results: Daughter fragments of regorafenib (m/z 481.1 > 194, m/z 481.1 > 260) and sorafenib (m/z 463 > 193.99, m/z 463 > 268.1) were determined in negative electrospray ionization mode. Linear calibration curve of range 50-2500 ng/ml was prepared in plasma. Method was selective, since there was no interfering peak at regorafenib retention time. Coefficient of variation for inter-day precision at three quality control concentrations were 17.6% at lower limit of quantitation, 6.3% at middle limit, and 2.9% at highest limit of quantitation. Accuracy of the method ranges between 96% to 105.3%. Recovery of drug from blank plasma at quality control concentrations varies between 82.53 to 105.66%. Conclusion: The developed method was successfully validated by adopting US FDA guidance for bioanalytical methods. The method is simple, quick and can be adopted for regorafenib estimation in other biological fluids with necessary modifications.
- 31 October 2018
- Published by Springer Nature in Pharmacological Reports
- Vol. 71 (2) , 201-205
Dasatinib significantly reduced in vivo exposure to cyclosporine in a rat model: The possible involvement of CYP3A induction
Background: This study was designed to investigate the effects of dasatinib and nilotinib on the pharmacokinetics of cyclosporine in rats, as these drugs have been reported to be cytochrome P450 3 A4 (CYP3 A4) substrates. Methods: Control and test groups (n = 5) were treated with vehicle and dasatinib (4 mg/kg, and 16 mg/kg, oral) or nilotinib (94 mg/kg, oral), respectively, for 8 consecutive days. On day 8, all groups were administered cyclosporine (30 mg/kg) 1 h after the last dose of dasatinib or nilotinib. Blood was collected from the retro-orbital plexus in heparinized tubes at different time points (0, 0.5, 1, 1.5, 2, 3.5, 8, 12, and 24 h). The cyclosporine concentration in blood samples was determined by ultra-performance liquid chromatography–tandem mass spectrometry. The effects of dasatinib on CYP3 A2 mRNA and protein expression levels were also investigated. Results: Dasatinib significantly reduced the maximum blood concentration (Cmax) of cyclosporine by 85.7 %, and increased hepatic and intestinal CYP3 A2 mRNA and protein expression levels by 2.4- and 1.25-fold, respectively, compared to those in the controls (p < 0.05). On the other hand, nilotinib had no significant effects on cyclosporine pharmacokinetic parameters. Conclusions: Dasatinib significantly reduced cyclosporine exposure, which was most probably related to the induction of CYP3 A-mediated cyclosporine metabolism.
- 31 October 2018
- Published by Springer Nature in Pharmacological Reports
- Vol. 71 (2) , 201-205
Dasatinib significantly reduced in vivo exposure to cyclosporine in a rat model: The possible involvement of CYP3A induction
Background: This study was designed to investigate the effects of dasatinib and nilotinib on the pharmacokinetics of cyclosporine in rats, as these drugs have been reported to be cytochrome P450 3 A4 (CYP3 A4) substrates. Methods: Control and test groups (n = 5) were treated with vehicle and dasatinib (4 mg/kg, and 16 mg/kg, oral) or nilotinib (94 mg/kg, oral), respectively, for 8 consecutive days. On day 8, all groups were administered cyclosporine (30 mg/kg) 1 h after the last dose of dasatinib or nilotinib. Blood was collected from the retro-orbital plexus in heparinized tubes at different time points (0, 0.5, 1, 1.5, 2, 3.5, 8, 12, and 24 h). The cyclosporine concentration in blood samples was determined by ultra-performance liquid chromatography–tandem mass spectrometry. The effects of dasatinib on CYP3 A2 mRNA and protein expression levels were also investigated. Results: Dasatinib significantly reduced the maximum blood concentration (Cmax) of cyclosporine by 85.7 %, and increased hepatic and intestinal CYP3 A2 mRNA and protein expression levels by 2.4- and 1.25-fold, respectively, compared to those in the controls (p < 0.05). On the other hand, nilotinib had no significant effects on cyclosporine pharmacokinetic parameters. Conclusions: Dasatinib significantly reduced cyclosporine exposure, which was most probably related to the induction of CYP3 A-mediated cyclosporine metabolism.
- 15 June 2016
- Published by IMR Press in International Journal of Pharmacology
- Vol. 12 (5) , 567-571
Analgesic Effect of Melanin from (Nigella sativa L.) in the Hotplate Test in Mice (Possible Opioid Receptor Involvement)
- 15 June 2016
- Published by IMR Press in International Journal of Pharmacology
- Vol. 12 (5) , 567-571
Analgesic Effect of Melanin from (Nigella sativa L.) in the Hotplate Test in Mice (Possible Opioid Receptor Involvement)